Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VXRT Vaxart Inc
- Stocks
- Healthcare
- NASDAQ: VXRT
Price (delayed)
$0.5067
Market cap
$115.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.27
Enterprise value
$103.77M
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can
Highlights
VXRT's gross profit has surged by 65% since the previous quarter
VXRT's revenue has surged by 65% since the previous quarter
VXRT's quick ratio has dropped by 78% year-on-year and by 16% since the previous quarter
The equity has contracted by 23% from the previous quarter and by 18% YoY
Key stats
What are the main financial stats of VXRT
Market
Valuations
Earnings
Shares outstanding
228.22M
Market cap
$115.64M
Enterprise value
$103.77M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.53
Price to sales (P/S)
2.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.19
Revenue
$47.4M
Gross profit
$47.4M
Operating income
-$57.16M
Net income
-$58.12M
EBIT
-$57.81M
EBITDA
-$48.89M
Free cash flow
-$33.73M
Per share
Balance sheet
Liquidity
EPS
-$0.27
EPS diluted
-$0.27
Free cash flow per share
-$0.15
Book value per share
$0.2
Revenue per share
$0.21
TBVPS
$0.66
Total assets
$158.56M
Total liabilities
$112.94M
Debt
$16.83M
Equity
$45.62M
Working capital
-$35.86M
Debt to equity
0.37
Current ratio
0.64
Quick ratio
0.59
Net debt/EBITDA
0.24
Margins
Efficiency
Dividend
EBITDA margin
-103.2%
Gross margin
100%
Net margin
-122.6%
Operating margin
-120.6%
Return on assets
-38.4%
Return on equity
-91.9%
Return on invested capital
-96.6%
Return on capital employed
-96.3%
Return on sales
-122%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VXRT stock price
How has the Vaxart stock price performed over time
Intraday
1.38%
1 week
21.95%
1 month
47.34%
1 year
-43.49%
YTD
-23.47%
QTD
24.5%
Financial performance
How have Vaxart's revenue and profit performed over time
Revenue
$47.4M
Gross profit
$47.4M
Operating income
-$57.16M
Net income
-$58.12M
Gross margin
100%
Net margin
-122.6%
VXRT's net margin has soared by 87% YoY and by 47% QoQ
The operating margin has surged by 87% year-on-year and by 48% since the previous quarter
VXRT's gross profit has surged by 65% since the previous quarter
VXRT's revenue has surged by 65% since the previous quarter
Price vs fundamentals
How does VXRT's price correlate with its fundamentals
Growth
What is Vaxart's growth rate over time
Valuation
What is Vaxart stock price valuation
P/E
N/A
P/B
2.53
P/S
2.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.19
The EPS has increased by 49% year-on-year and by 18% since the previous quarter
The P/B is 32% below the 5-year quarterly average of 3.7 but 14% above the last 4 quarters average of 2.2
The equity has contracted by 23% from the previous quarter and by 18% YoY
VXRT's P/S is 99% below its 5-year quarterly average of 445.2 and 64% below its last 4 quarters average of 6.7
VXRT's revenue has surged by 65% since the previous quarter
Efficiency
How efficient is Vaxart business performance
The return on sales has surged by 87% year-on-year and by 48% since the previous quarter
The ROA has soared by 52% YoY and by 23% from the previous quarter
Vaxart's ROE has increased by 24% YoY and by 10% from the previous quarter
The company's return on invested capital rose by 23% YoY and by 7% QoQ
Dividends
What is VXRT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VXRT.
Financial health
How did Vaxart financials performed over time
The company's total assets is 40% higher than its total liabilities
Vaxart's current ratio has shrunk by 80% YoY and by 15% QoQ
The company's total assets has surged by 79% YoY but it fell by 4.7% QoQ
VXRT's debt is 63% lower than its equity
Vaxart's debt to equity has increased by 23% QoQ and by 6% YoY
The equity has contracted by 23% from the previous quarter and by 18% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.